Showing results (211-220 of 233) with videos related to

Sort By:
Pageof 24
Cancer Immunology Research|April 17, 2019
Siglec-9 Regulates an Effector Memory CD8+ T-cell Subset That Congregates in the Melanoma Tumor MicroenvironmentQuentin Haas, Kayluz Frias Boligan, Camilla Jandus, et al.
Bone Marrow Transplantation|May 11, 2020
Risk stratification using FLT3 and NPM1 in acute myeloid leukemia patients autografted in first complete remissionRoni Shouval, Myriam Labopin, David Bomze, et al.
Scientific Reports|September 10, 2017
Complete sequence-based pathway analysis by differential on-chip DNA and RNA extraction from a single cellD van Strijp, R C M Vulders, N A Larsen, et al.
The Journal of Clinical Investigation|May 27, 2015
IL-33 signaling contributes to the pathogenesis of myeloproliferative neoplasmsLukas F Mager, Carsten Riether, Christian M Schürch, et al.
Journal of Vascular and Interventional Radiology : JVIR|August 1, 2017
Proposal of a New Adverse Event Classification by the Society of Interventional Radiology Standards of Practice CommitteeOmid Khalilzadeh, Mark O Baerlocher, Paul B Shyn, et al.
Annals of Nutrition & Metabolism|June 9, 2012
Documentation of functional and clinical effects of infant nutrition: setting the scene for COMMENTBerthold Koletzko, Hania Szajewska, Margaret Ashwell, et al.
Annals of Hematology|March 25, 2014
Older patients with chronic myeloid leukemia (≥65 years) profit more from higher imatinib doses than younger patients: a subanalysis of the randomized CML-Study IVUlrike Proetel, Nadine Pletsch, Michael Lauseker, et al.
Leukemia|September 11, 2020
Correction: High-risk additional chromosomal abnormalities at low blast counts herald death by CMLRüdiger Hehlmann, Astghik Voskanyan, Michael Lauseker, et al.
Leukemia|May 9, 2020
High-risk additional chromosomal abnormalities at low blast counts herald death by CMLRüdiger Hehlmann, Astghik Voskanyan, Michael Lauseker, et al.
Leukemia|May 7, 2014
Velocity of early BCR-ABL transcript elimination as an optimized predictor of outcome in chronic myeloid leukemia (CML) patients in chronic phase on treatment with imatinibB Hanfstein, V Shlyakhto, M Lauseker, et al.
Pageof 24